The Utility of Prophylactic Antibiotics for Laparoscopic Pyloromyotomy

Kristine L Griffin1, Brandon Rodgers2, Hannah Rinehardt3

  • 1Department of Pediatric Surgery, Nationwide Children's Hospital, Columbus, Ohio.

Insights

Preoperative antibiotics do not impact surgical site infection rates in laparoscopic pyloromyotomy for infantile hypertrophic pyloric stenosis. Antibiotic use varies widely among surgeons, suggesting a need for standardized protocols to reduce unnecessary prophylaxis.

Area of Science:

  • Pediatric Surgery
  • Surgical Infections
  • Antibiotic Stewardship

Background:

  • Laparoscopic pyloromyotomy (LP) for infantile hypertrophic pyloric stenosis (IHPS) is a low-risk procedure for surgical site infections (SSI).
  • Existing literature shows varied use of prophylactic antibiotics for LP, despite low expected SSI rates.

Purpose of the Study:

  • To evaluate the association between preoperative antibiotic administration and SSI incidence in patients undergoing LP for IHPS.
  • To identify variations in prophylactic antibiotic utilization among surgeons performing LP.

Main Methods:

  • Retrospective analysis of 227 patients under 4 months old who underwent LP for IHPS from January 2017 to June 2020.
  • Exclusion of patients lost to follow-up or requiring intraoperative conversion to open surgery.
  • Statistical analysis using Fisher's exact test and independent t-tests to compare SSI rates and patient characteristics.

Main Results:

  • Preoperative antibiotics were given to 39% of patients; overall SSI rate was 1.3%.
  • No significant difference in SSI rates was observed between patients who received preoperative antibiotics (1.1%) and those who did not (1.4%).
  • Significant variability in antibiotic prescribing practices was noted among individual surgeons.

Conclusions:

  • Preoperative antibiotic use in laparoscopic pyloromyotomy for IHPS is not associated with a reduction in surgical site infection rates.
  • Current antibiotic utilization for LP demonstrates considerable variation, indicating a need for updated guidelines to optimize prophylactic antibiotic use.
Abstract

Related Concept Videos

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
368
Peptic Ulcer Disease V: Surgical Management and Nursing Care01:25

Peptic Ulcer Disease V: Surgical Management and Nursing Care

Surgical management and nursing care are crucial in treating Peptic Ulcer Disease (PUD). Here is an organized and enhanced overview of the surgical interventions and the associated nursing care for PUD:
Surgical Interventions for Peptic Ulcer Disease
292
Endoscopic Procedures IV: Sigmoidoscopy and Laproscopy01:26

Endoscopic Procedures IV: Sigmoidoscopy and Laproscopy

Sigmoidoscopy and laparoscopy are distinct medical procedures that enable physicians to internally inspect different parts of the GI tract. Although they serve different purposes, each is essential for diagnosing and, in some cases, treating various medical conditions.
Sigmoidoscopy
Sigmoidoscopy is a diagnostic procedure that uses a flexible sigmoidoscope equipped with a light source and camera to examine the rectum and sigmoid colon. The procedure involves inserting the tube through the anus...
73
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
88
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
408